UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial

JAMA oncology, 2022-11, Vol.8 (11), p.1571

2022

Volltextzugriff (PDF)

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

JAMA oncology, 2023-10, Vol.9 (10), p.1356

2023

Volltextzugriff (PDF)

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

The lancet. Gastroenterology & hepatology, 2019-06, Vol.4 (6), p.454-465

2019

Volltextzugriff (PDF)

A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal

Critical care (London, England), 2013-01, Vol.17 (1), p.R4-R4, Article R4

2013

Volltextzugriff (PDF)

Hepatogastroenterologists' knowledge of inactive carriers and immunotolerant hepatitis B virus patients in France: results of a practice survey

European journal of gastroenterology & hepatology, 2015-05, Vol.27 (5), p.544-549

2015

Volltextzugriff (PDF)

Treatment with intravenous rt-PA in a general hospital context: A review of the Saint-Jean Hospital experience from Perpignan, France

Revue neurologique, 2006-11, Vol.162 (11), p.1109-1117

2006

Volltextzugriff (PDF)

Utilisation du rt-PA intraveineux dans l’ischémie cérébrale en Centre Hospitalier Général : l’expérience de l’Hôpital Saint-Jean de Perpignan

Revue neurologique, 2006-11, Vol.162 (11), p.1109-1117

2006

Volltextzugriff (PDF)

Apport de l’IRM multimodale et facteurs prédictifs pour le diagnostic d’accident vasculaire cérébral ischémique lors d’un vertige aigu isolé au service d’accueil des urgences : étude prospective monocentrique au CH de Perpignan

Revue neurologique, 2013-04, Vol.169, p.A83-A83

2013

Volltextzugriff (PDF)

Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma

Journal of hepatology, 2019-09, Vol.71 (3), p.516-522

2019

Volltextzugriff (PDF)

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

The New England journal of medicine, 2018-12, Vol.379 (25), p.2395-2406

2018

Volltextzugriff (PDF)

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

The New England journal of medicine, 2011-05, Vol.364 (19), p.1817-1825

2011

Volltextzugriff (PDF)

Comparative Efficacy and Long-Term Oncological Safety of Extended Right Hemicolectomy Versus Left Colectomy for Splenic Flexure Adenocarcinoma: A Systematic Review and Meta-Analysis

Cancer control, 2024-01, Vol.31, p.10732748241287019

2024

Volltextzugriff (PDF)

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer

European journal of cancer (1990), 2018-07, Vol.97, p.16-24

2018

Volltextzugriff (PDF)

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

Annals of oncology, 2018-01, Vol.29 (1), p.133-138

2018

Volltextzugriff (PDF)

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

Digestive and liver disease, 2022-03, Vol.54 (3), p.324-330

2022

Volltextzugriff (PDF)

507O Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer: Final results of the phase II randomized multicenter LEANOX trial

Annals of oncology, 2024-09, Vol.35, p.S431-S431

2024

Volltextzugriff (PDF)

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

Journal of clinical oncology, 2022-01, Vol.40 (3), p.262-271

2022

Volltextzugriff (PDF)

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

European journal of cancer (1990), 2020-09, Vol.136, p.25-34

2020

Volltextzugriff (PDF)

Optimization of Carob (Ceratonia siliqua L.) Pulp Powder Roasting to Improve Its Quality by Using Central Composite Design

Food and bioprocess technology, 2023-06, Vol.16 (6), p.1292-1302

2023

Volltextzugriff (PDF)

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results

Annals of oncology, 2018-11, Vol.29 (11), p.2270-2270

2018

Volltextzugriff (PDF)

502O Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial

Annals of oncology, 2024-09, Vol.35, p.S428-S428

2024

Volltextzugriff (PDF)

Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e16195-e16195

2024

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Englisch
(50)
Französisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(25)
Humans
(20)
Male
(18)
Female
(17)
Aged
(16)
Middle Aged
(14)
Life Sciences
(12)
Oncology
(10)
Aged, 80 And Over
(9)
Cancer
(9)
Adult
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Chemotherapy
(6)
Fluorouracil - Administration & Dosage
(6)
Gastroenterology & Hepatology
(6)
Leucovorin - Administration & Dosage
(6)
Metastases
(6)
Patients
(6)
Survival
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal

Hepatogastroenterologists' knowledge of inactive carriers and immunotolerant hepatitis B virus patients in France: results of a practice survey

Treatment with intravenous rt-PA in a general hospital context: A review of the Saint-Jean Hospital experience from Perpignan, France

Utilisation du rt-PA intraveineux dans l’ischémie cérébrale en Centre Hospitalier Général : l’expérience de l’Hôpital Saint-Jean de Perpignan

Apport de l’IRM multimodale et facteurs prédictifs pour le diagnostic d’accident vasculaire cérébral ischémique lors d’un vertige aigu isolé au service d’accueil des urgences : étude prospective monocentrique au CH de Perpignan

Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Comparative Efficacy and Long-Term Oncological Safety of Extended Right Hemicolectomy Versus Left Colectomy for Splenic Flexure Adenocarcinoma: A Systematic Review and Meta-Analysis

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer

First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

507O Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer: Final results of the phase II randomized multicenter LEANOX trial

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Optimization of Carob (Ceratonia siliqua L.) Pulp Powder Roasting to Improve Its Quality by Using Central Composite Design

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results

502O Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial

Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC)

Suchergebnisse filtern